Compare MasTec Inc (MTZ) vs Zoetis Inc (ZTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
MasTec Inc vs Zoetis Inc — how do they compare? MasTec Inc trades at $281.27 (market cap $21.90B), while Zoetis Inc trades at $73.27 (market cap $31.14B). The key difference: Zoetis Inc is the larger of the two by market cap, and Zoetis Inc pays a 2.81% dividend while MasTec Inc pays none. Which is the better fit depends on your goals.
| MTZ | ZTS | |
|---|---|---|
Market Cap | $21.90B | $31.14B |
Sector | Technology | Health |
52-Week High | $437.51 | $156.76 |
52-Week Low | $172.51 | $71.91 |
Enterprise Value | $24.81B | $38.70B |
Dividend Yield | — | 2.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MTZ trades at $282.66, up 5.36% over 24 hours, with a bearish technical signal but strong fundamental momentum. The company reported record Q2 2026 revenue of $4.37 billion, up 23% year-over-year, and raised its full-year outlook, supported by a $21.4 billion backlog and recent acquisition of The Superior Group. Analyst consensus is overwhelmingly bullish with a $439.56 price target, though technical indicators show selling pressure near resistance at $283.
The outlook for MTZ is positive, driven by infrastructure demand and earnings beats, but risks include execution on large projects and debt from recent note issuance. The stock offers growth potential if it can sustain margin expansion and capitalize on its record backlog, though investors should monitor communications segment delays and interest expense impacts.
Zoetis (ZTS) trades at $72.42, down 3.27% amid bearish technical signals and recent earnings pressure. The stock shows strong fundamentals with 27.69% net margins and 64.91% ROE, but faces headwinds from softening pet healthcare demand. Recent Q2 2026 earnings beat estimates but revenue missed, prompting a lowered 2026 outlook. Analyst consensus remains positive with a $94.90 price target despite near-term challenges.
The outlook remains cautiously optimistic given ZTS's dominant market position and profitability, though near-term performance depends on reversing companion animal segment weakness. Investment opportunity exists at current discounted valuation (P/E 12.29), balanced against competitive pressures and class action litigation risks. Upside potential aligns with analyst targets if execution improves.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About MasTec Inc
MasTec, Inc. is a leading infrastructure construction company operating mainly in North America. The company's services cover a diverse range of end-markets, including communications (building fiber and wireless infrastructure), oil & gas, electric power (transmission, distribution, and clean energy), and industrial projects. MTZ provides critical engineering, procurement, and construction (EPC) services that support the expansion and maintenance of essential infrastructure across the continent.
Read more on MTZ →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
